文献速递类风湿关节炎脊柱关节炎其他结缔组织病

成人免疫介导性风湿病中的颞下颌关节紊乱:一项系统综述

Temporomandibular disorders in immune-mediated rheumatic diseases of the adult: A systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2023-05-05

本系统综述检索了PubMed Central、Embase和Cochrane Library数据库,纳入56篇文献,评估成人免疫介导性风湿病中颞下颌关节紊乱(TMDs)的患病率、临床研究结局及危险因素。类风湿关节炎中TMDs体征和症状患病率为8%至70%,脊柱关节炎为12%至80%,系统性硬化症患者报告结局和临床发现为20%至93%,系统性红斑狼疮为18%至85%。TMDs在风湿病临床实践中具有显著相关性,但常被误诊,早期识别和多学科管理是必要的。

要点

  • 类风湿关节炎中TMDs患病率8%至70%,危险因素包括女性、年轻、ACPA阳性、高疾病活动度等。
  • 脊柱关节炎中TMDs症状和体征患病率12%至80%,与放射学脊柱受累、皮肤银屑病和HLA-DRB1×01阳性相关。
  • 系统性硬化症TMDs患者报告结局和临床发现20%至93%,系统性红斑狼疮18%至85%,原发性干燥综合征24%至54%,特发性炎性肌病4%至26%。

核心结论

  • TMDs在免疫介导性风湿病中对风湿病临床实践具有显著相关性,尽管常被误诊。
  • TMDs的疾病负担在流行病学上具有重要性,其患者报告结局和临床发现与类风湿关节炎、脊柱关节炎、系统性硬化症和系统性红斑狼疮的疾病活动度相关。
  • TMDs的早期识别和多学科管理是必要的,应旨在阻止颞下颌关节结构损伤,最大化患者的生活质量。

研究设计与样本

  • 系统综述,检索PubMed Central、Embase和Cochrane Library数据库,纳入评估免疫介导性风湿病患者颞下颌关节结局的研究。
  • 纳入与健康对照、其他风湿病比较或评估免疫介导性风湿病患者随访和治疗后颞下颌关节结局的研究。
  • 纳入研究成人免疫介导性风湿病中炎性多关节炎和/或自身免疫性结缔组织病的原始文章。
  • 使用纽卡斯尔-渥太华量表(NOS)对研究质量进行评分。
  • 筛选3259篇摘要,最终纳入56篇论文。

主要发现

  • 大多数论文(77%)研究类风湿关节炎中的TMDs,体征和症状患病率从8%到70%不等。
  • 类风湿关节炎中TMDs发展的危险因素为女性、较年轻年龄、抗瓜氨酸肽自身抗体(ACPA)阳性、较高疾病活动度、颈椎受累、心血管和神经精神共病。
  • 十篇论文(18%)评估脊柱关节炎中的TMDs,报告症状和体征患病率为12%至80%,放射学脊柱受累、皮肤银屑病和HLA-DRB1×01阳性患者中TMDs患病率更高。
  • 在自身免疫性结缔组织病中,系统性硬化症显示最高的TMDs患者报告结局和临床发现证据(20%至93%),其次为系统性红斑狼疮18%至85%、原发性干燥综合征24%至54%和特发性炎性肌病4%至26%。
  • 在系统性硬化症和系统性红斑狼疮中,TMDs在较高疾病活动度和病程较长的患者中更常见,分别与系统性硬化症皮肤纤维化范围和系统性红斑狼疮肾脏受累相关。

关键数值与推荐

  • 类风湿关节炎中TMDs体征和症状患病率为8%至70%。
  • 脊柱关节炎中TMDs症状和体征患病率为12%至80%。
  • 系统性硬化症中TMDs患者报告结局和临床发现为20%至93%。
  • 系统性红斑狼疮中TMDs为18%至85%。
  • 原发性干燥综合征中TMDs为24%至54%,特发性炎性肌病中TMDs为4%至26%。

临床怎么用

  • TMDs的早期识别和多学科管理是必要的,应旨在阻止颞下颌关节结构损伤,最大化患者的生活质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To systematically review the literature concerning temporomandibular disorders (TMDs) in immune-mediated rheumatic diseases (IMRDs) of the adult. The temporomandibular joint (TMJ) outcomes used in clinical studies, the prevalence of TMDs in IMRDs and the risk factors for their development were qualitatively synthetized. METHODS: A literature search on PubMed Central, Embase and Cochrane Library databases was performed for studies including TMJ outcomes in IMRDs patients compared with healthy controls, other rheumatic diseases or in the assessed IMRDs patients after follow-up and treatment. Among the IMRDs of the adult, original articles investigating TMJ involvement in inflammatory polyarthritides and/or autoimmune connective tissue diseases were considered. The quality of the studies was scored using the Newcastle-Ottawa scale (NOS). RESULTS: Of the 3259 screened abstracts, 56 papers were included in the systematic review. Most of the papers (77%) investigated TMDs in rheumatoid arthritis (RA) with a prevalence of signs and symptoms varying from 8% to 70%. The risk factors for TMDs development in RA were female sex, younger age, anti-citrulline peptide autoantibodies (ACPA) positivity, higher disease activity, cervical spine involvement, cardiovascular and neuropsychiatric comorbidities. Ten papers (18%) evaluated TMDs in spondylarthritides (SpA) reporting a prevalence of symptoms and signs in 12%-80% of patients with higher TMDs prevalence in patients with radiographic spine involvement, skin psoriasis and HLADRB1×01 positivity. Among autoimmune connective tissue diseases (CTDs), systemic sclerosis (SSc) displayed the highest evidence of TMDs patient-reported outcomes (PROs) and clinical findings (20-93%), followed by systemic lupus erythematosus (SLE) in 18-85%, primary Sjogren's syndrome (24-54%) and idiopathic inflammatory myopathies (4-26%). In SSc and SLE, TMDs were more frequent in patients with higher disease activity and duration, correlating with the extent of skin fibrosis in SSc and with renal involvement in SLE. CONCLUSION: TMDs in IMRDs display a significant relevance in the rheumatological clinical practice even if often misdiagnosed. This burden is epidemiologically important in terms of PROs and clinical findings which correlate with disease activity in RA, SpA, SSc and SLE. The early recognition and multidisciplinary management of TMDs is warranted and should be aimed at hindering the TMJ structural damage maximizing the quality of life of patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Hysa E, Lercara A, Cere A, et al. Temporomandibular disorders in immune-mediated rheumatic diseases of the adult: A systematic review. Semin Arthritis Rheum. 2023. PMID: 37167773. doi:10.1016/j.semarthrit.2023.152215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。